Z-Endoxifen

Phase 2Small molecule

AAtossa Therapeutics, Inc.

Z-Endoxifen is one of 59 small molecule programs targeting Breast Neoplasms. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast NeoplasmsActive, not recruiting

Ductal Carcinoma in SituRecruiting

Menopausal WomenActive, not recruiting

Breast CancerRecruiting

Breast NeoplasmsPhase 2

Active, not recruiting

Ductal Carcinoma in SituPhase 2

Recruiting

Menopausal WomenPhase 2

Active, not recruiting

Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Z-Endoxifen

AAtossa Therapeutics, Inc.

Phase 2

1 2

Adenocard

Astellas

Preclinical

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 5

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 6

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 7

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 8

Bisphosphonate

Amgen

Preclinical

2 9

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Breast Neoplasms

NCT05607004

Q4 2031

Phase 2Recruiting

Breast Cancer

NCT01042379

Q4 2033

Phase 2Recruiting

Ductal Carcinoma in Situ

NCT06075953

Clinical

Trials by Indication[1]

Hormone Receptor Positive1 trial

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01273168·40 enrolled

Menopausal Women1 trial

Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

Active, not recruiting·AAtossa Therapeutics, Inc.·Phase 2·NCT05068388·240 enrolled

Breast Cancer1 trial

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT01042379·5,000 enrolled

Ductal Carcinoma in Situ1 trial

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT06075953·400 enrolled

Breast Neoplasms1 trial

A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer

Active, not recruiting·AAtossa Therapeutics, Inc.·Phase 2·NCT05607004·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Z-Endoxifen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Z-Endoxifen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Z-Endoxifen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atossa Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAtossa Therapeutics, Inc.

Z-Endoxifen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2031

Q4 2033

Trials by Indication[1]

Hormone Receptor Positive1 trial

Menopausal Women1 trial

Breast Cancer1 trial

Ductal Carcinoma in Situ1 trial

Breast Neoplasms1 trial

References

Drug Info

Quick Facts

Related News